Commodore Capital LP Trims Stake in Pharvaris N.V. $PHVS

Commodore Capital LP lowered its holdings in Pharvaris N.V. (NASDAQ:PHVS) by 21.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,889,445 shares of the company’s stock after selling 529,031 shares during the period. Pharvaris makes up 3.5% of Commodore Capital LP’s investment portfolio, making the stock its 15th largest position. Commodore Capital LP’s holdings in Pharvaris were worth $52,432,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Boothbay Fund Management LLC increased its position in shares of Pharvaris by 16.2% in the fourth quarter. Boothbay Fund Management LLC now owns 157,117 shares of the company’s stock worth $4,360,000 after purchasing an additional 21,936 shares during the last quarter. ADAR1 Capital Management LLC boosted its position in Pharvaris by 150.6% during the fourth quarter. ADAR1 Capital Management LLC now owns 85,528 shares of the company’s stock valued at $2,373,000 after buying an additional 51,404 shares during the period. Trexquant Investment LP bought a new position in shares of Pharvaris during the fourth quarter valued at about $2,341,000. Jump Financial LLC bought a new position in shares of Pharvaris during the fourth quarter valued at about $730,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Pharvaris by 15.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 941,605 shares of the company’s stock worth $26,130,000 after buying an additional 124,797 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating on shares of Pharvaris in a research report on Tuesday. Wolfe Research started coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Wedbush lifted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. UBS Group set a $74.00 price objective on shares of Pharvaris in a report on Wednesday, May 13th. Finally, Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Insider Transactions at Pharvaris

In other news, CFO David W. Nassif sold 10,000 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.31, for a total transaction of $303,100.00. Following the completion of the transaction, the chief financial officer directly owned 120,300 shares in the company, valued at $3,646,293. This trade represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Berndt Modig sold 2,291 shares of Pharvaris stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $31.07, for a total value of $71,181.37. Following the completion of the transaction, the chief executive officer directly owned 135,209 shares of the company’s stock, valued at approximately $4,200,943.63. This represents a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 214,909 shares of company stock valued at $6,421,745. 11.84% of the stock is currently owned by corporate insiders.

Pharvaris Stock Performance

Shares of PHVS opened at $33.41 on Thursday. Pharvaris N.V. has a fifty-two week low of $16.00 and a fifty-two week high of $33.50. The firm’s 50-day simple moving average is $29.81 and its two-hundred day simple moving average is $27.67. The stock has a market cap of $2.19 billion, a PE ratio of -10.51 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. Equities research analysts predict that Pharvaris N.V. will post -3.22 EPS for the current year.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.